{
  "report_rows": [
    {
      "kpi": "Q2 2026 Total Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$120M vs. cons $105.5M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Operating EPS (Diluted)",
      "prediction": "BEAT",
      "answer": "pred ~-$1.70 vs. cons -$1.89",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Adj. Cash Cost (run-rate)",
      "prediction": "BEAT",
      "answer": "pred on-track / slight beat vs. $4.2B FY target",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Revenue (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "guide 'up to 10% growth' reiterated vs. cons $2,088M \u2014 implicit H2 cut embedded",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY 2026 Adj. Cash Cost (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$4.2B reiterated vs. cons ~$4.2B",
      "confidence": "HIGH"
    },
    {
      "kpi": "mRNA-1010 Flu Tone (qualitative)",
      "prediction": "BETTER",
      "answer": "confident language post-9-0 VRBPAC vs. prior 'encouraged'",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": -0.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 9.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 flu PDUFA (Aug 5) within the 5-day window drives recovery; base case is approval given 9-0 VRBPAC vote",
  "day5_confidence": "MEDIUM"
}